{
    "id": 17993,
    "fullName": "ETV6 - ABL1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ETV6-ABL1 results from the fusion of ETV6 (also referred to as TEL) and ABL1, demonstrating increased kinase activity (PMID: 9695962) and the ability to induce CML-like myeloproliferative disease in mice (PMID: 12036890) and in cell culture (PMID: 9695962).",
            "references": [
                {
                    "id": 4586,
                    "pubMedId": 12036890,
                    "title": "The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12036890"
                },
                {
                    "id": 12151,
                    "pubMedId": 9695962,
                    "title": "Haemopoietic transformation by the TEL/ABL oncogene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9695962"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2120,
        "geneSymbol": "ETV6",
        "terms": [
            "ETV6",
            "TEL",
            "TEL/ABL",
            "THC5"
        ]
    },
    "variant": "ETV6 - ABL1",
    "createDate": "02/14/2016",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 25,
                "geneSymbol": "ABL1",
                "terms": [
                    "ABL1",
                    "ABL",
                    "BCR-ABL",
                    "bcr/abl",
                    "c-ABL",
                    "c-ABL1",
                    "CHDSKM",
                    "JTK7",
                    "p150",
                    "v-abl"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 13784,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tasigna (nilotinib) treatment resulted in a complete hematological response after 4 weeks of treatment and sustained complete cytogenetic response and major molecular response at 22 months from diagnosis in a patient with chronic myeloid leukemia harboring ETV6-ABL1, whose disease progressed while on Gleevec (imatinib mesylate) at 6 months from diagnosis (PMID: 24053143).",
            "molecularProfile": {
                "id": 18323,
                "profileName": "ETV6 - ABL1"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11275,
                    "pubMedId": 24053143,
                    "title": "Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24053143"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13783,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with chronic myeloid leukemia harboring ETV6-ABL1 achieved a complete hematological response after 4 weeks of Gleevec (imatinib mesylate) treatment, but the disease progressed at 6 months (PMID: 24053143).",
            "molecularProfile": {
                "id": 18323,
                "profileName": "ETV6 - ABL1"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 8552,
                "name": "chronic myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11275,
                    "pubMedId": 24053143,
                    "title": "Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24053143"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18323,
            "profileName": "ETV6 - ABL1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}